- Home
- LNZA vs CURX Comparison
LNZA vs CURX Comparison
Compare LNZA & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNZA | CURX |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 29.7M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | LNZA | CURX |
|---|---|---|
| Price | $14.60 | $0.46 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 11.9K | ★ 2.7M |
| Earning Date | 11-19-2025 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,876,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $113.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.20 | $3.61 |
| 52 Week High | $274.00 | $8.60 |
Technical Indicators
Market Signals| Indicator | LNZA | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | N/A |
| Support Level | $13.37 | N/A |
| Resistance Level | $15.32 | N/A |
| Average True Range (ATR) | 1.43 | 0.00 |
| MACD | 0.48 | 0.00 |
| Stochastic Oscillator | 81.15 | 0.00 |
Price Performance
Historical ComparisonAbout LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About CURX Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.